Eric Alton is Professor of Gene Therapy and Respiratory Medicine, National Heart & Lung Institute, Imperial College London and Honorary Consultant Physician, Royal Brompton Hospital
Professor Alton was educated at Jesus College, Cambridge and Westminster Medical School and subsequently undertook six years of general medical training. Over the last fifteen years, he has been involved in developing gene therapy for cystic fibrosis and angiogenesis, including three clinical trials.
Professor Alton coordinates the UK CF Gene Therapy Consortium which brings together the three centres in the UK (Edinburgh and Oxford Universities and Imperial College), including approximately 80 clinicians and scientists focused on this problem.
et al., 2016, Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung, Antimicrobial Agents and Chemotherapy, Vol:60, ISSN:0066-4804, Pages:744-751
et al., 2015, Multiple breath washouts in children can be shortened without compromising quality, European Respiratory Journal, Vol:46, ISSN:0903-1936, Pages:1814-1816
et al., 2015, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF REPEATED NEBULISATION OF NON-VIRAL CFTR GENE THERAPY IN PATIENTS WITH CYSTIC FIBROSIS, Pediatric Pulmonology, Vol:50, ISSN:8755-6863, Pages:262-262
et al., 2015, Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Respiratory Medicine, Vol:3, ISSN:2213-2600, Pages:684-691
et al., 2015, A Phase I/IIa Safety and Efficacy Study of Nebulized Liposome-mediated Gene Therapy for Cystic Fibrosis Supports a Multidose Trail, American Journal of Respiratory and Critical Care Medicine, Vol:192, ISSN:1073-449X, Pages:1389-1392